Welcome to the official InxMed website
Pipeline

Pipeline

>
Company Activity

Company Activity

Ifebemtinib

Ifebemtinib (also known as IN10018, ifebe, BI853520) is  an orally administered, highly potent and selective small molecular inhibitor of the focal adhesion kinase (FAK). InxMed translational research has demonstrated the essential functions of FAK in tumor defense. 

OMTX705

OMTX705 is an ADC formed by a new humanized anti-FAP mAb that has been conjugated to a novel cytolysin, TAM470, a synthetic microtubule inhibitor from the tubulysin family. IN30705 is designed to target FAP-expressing Cancer Associated Fibroblasts (CAFs) in tumor microenvironment. 

NEXT GENERATION ADC

InxMed has developed ADC to address with aims of stronger, more potent ADC to overcome emerging resistance and companion biomarker test sparing.  

 InxMed

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world

QUICK LINKS

CONTACT US

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

MESSAGE

Follow Us:

CopyRight © 2022 InxMed All Rights Reserved.

Powered by: 300.cn | SEO